USA-based firms Millipore and Gen-Probe have entered into a deal under which the former will market the latter's Mycoplasma Tissue Culture Non-Isotopic test to those conducting biopharmaceutical research. The accord, financial terms of which were not provided, builds on the pre-existing partnership that the companies established in 2005 (Marketletters passim).
The firms added that the assay, which is a DNA-based probe system designed to identify the presence of micro-organisms during product manufacture, will allow biotechnology firms to cut contamination levels, thereby expediting the drug production process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze